Deletion of Fn14 receptor protects from right heart fibrosis and dysfunction

Basic Research in Cardiology

Volumn 108, Issue 2, 2013, Pages

  Novoyatleva, Tatyana ^a   Schymura, Yves ^a   Janssen, Wiebke ^a   Strobl, Frederic ^a   Swiercz, Jakub M ^a   Patra, Chinmoy ^a   Posern, Guido ^b   Wietelmann, Astrid ^a   Zheng, Timothy S ^c   Schermuly, Ralph T ^a,d   Engel, Felix B ^a,e  

^a MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^c BIOGEN   (United States)

^d JUSTUS LIEBIG UNIVERSITY   (Germany)

^e UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Cardiac fibroblasts; Fibrosis; Fn14; MAL; Right heart disease

Indexed keywords

COLLAGEN; ENDOTHELIN 1; FIBROBLAST GROWTH FACTOR INDUCIBLE 14 RECEPTOR; MYOCARDIN RELATED TRANSCRIPTION FACTOR A; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; MEMBRANE PROTEIN; MKL1 PROTEIN, MOUSE; MYOCARDIN RELATED TRANSCRIPTION FACTOR A, RAT; MYOCARDIN-RELATED TRANSCRIPTION FACTOR-A, RAT; TNFSF12 PROTEIN, MOUSE; TRANSACTIVATOR PROTEIN; TUMOR NECROSIS FACTOR; TWEAK PROTEIN, RAT; TWEAK RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CELL NUCLEUS; CELL PROLIFERATION; CONTROLLED STUDY; FIBROBLAST; GENE DELETION; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART RIGHT VENTRICLE FIBROSIS; LUNG ARTERY BANDING; MOUSE; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PULMONARY HYPERTENSION; RECEPTOR UPREGULATION; WILD TYPE; ANIMAL; CELL DIFFERENTIATION; FIBROSIS; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; HEART MUSCLE; HEART RIGHT VENTRICLE FUNCTION; HEART RIGHT VENTRICLE HYPERTROPHY; IMMUNOHISTOCHEMISTRY; METABOLISM; MOUSE MUTANT; MYOFIBROBLAST; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RAT; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT; UPREGULATION; WESTERN BLOTTING;

ANIMALS; APOPTOSIS REGULATORY PROTEINS; BLOTTING, WESTERN; CELL DIFFERENTIATION; CELL PROLIFERATION; COLLAGEN; ENDOTHELIN-1; FIBROSIS; FLUORESCENT ANTIBODY TECHNIQUE; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; IMMUNOHISTOCHEMISTRY; MEMBRANE PROTEINS; MICE; MICE, KNOCKOUT; MYOCARDIUM; MYOFIBROBLASTS; RATS; RATS, SPRAGUE-DAWLEY; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TUMOR NECROSIS FACTORS; UP-REGULATION; VENTRICULAR DYSFUNCTION, RIGHT;

MLCS; MLOWN;

EID: 84872163587     PISSN: 03008428     EISSN: 14351803     Source Type: Journal    
DOI: 10.1007/s00395-012-0325-x     Document Type: Article

References (55)

1. Bhatnagar S, Kumar A (2012) The TWEAK-Fn14 system: breaking the silence of cytokine-induced skeletal muscle wasting. Curr Mol Med 12:3-13. doi:10.2174/156652412798376107
2. Bishop SP, Melsen LR (1976) Myocardial necrosis, fibrosis, and DNA synthesis in experimental cardiac hypertrophy induced by sudden pressure overload. Circ Res 39:238-245. doi:10.1161/ 01.RES.39.2.238
3. Bogaard HJ, Abe K, Vonk Noordegraaf A, Voelkel NF (2009) The right ventricle under pressure: cellular and molecular mechanisms of right-heart failure in pulmonary hypertension. Chest 135:794-804. doi:10.1378/chest.08-0492
4. Burkly LC, Michaelson JS, Zheng TS (2011) TWEAK/Fn14 pathway: an immunological switch for shaping tissue responses. Immunol Rev 244:99-114. doi:10.1111/j.1600-065X.2011. 01054.x
5. Chen HN, Wang DJ, Ren MY, Wang QL, Sui SJ (2012) TWEAK/Fn14 promotes the proliferation and collagen synthesis of rat cardiac fibroblasts via the NF-small ka, Cyrillic B pathway. Mol Biol Rep 39:8231-8241. doi:10.1007/s11033-012-1671- 3
6. Chorianopoulos E, Heger T, Lutz M, Frank D, Bea F, Katus HA, Frey N (2010) FGF-inducible 14-kDa protein (Fn14) is regulated via the RhoA/ROCK kinase pathway in cardiomyocytes and mediates nuclear factor-kappaB activation by TWEAK. Basic Res Cardiol 105:301-313. doi:10.1007/s00395-009-0046-y
7. Correia-Pinto J, Henriques-Coelho T, Roncon-Albuquerque R Jr, Lourenco AP, Melo-Rocha G, Vasques-Novoa F, Gillebert TC, Leite-Moreira AF (2009) Time course and mechanisms of left ventricular systolic and diastolic dysfunction in monocrotalineinduced pulmonary hypertension. Basic Res Cardiol 104:535-545. doi:10.1007/s00395-009-0017-3
8. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Kernis JT, Levy PS, Pietra GG, Reid LM, Reeves JT, Rich S, Vreim CE, Williams GW, Wu M (1991) Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 115:343-349
9. Descot A, Hoffmann R, Shaposhnikov D, Reschke M, Ullrich A, Posern G (2009) Negative regulation of the EGFR-MAPK cascade by actin-MAL-mediated Mig6/Errfi-1 induction. Mol Cell 35:291-304. doi:10.1016/j.molcel.2009.07.015
10. Emoto N, Raharjo SB, Isaka D, Masuda S, Adiarto S, Jeng AY, Yokoyama M (2005) Dual ECE/NEP inhibition on cardiac and neurohumoral function during the transition from hypertrophy to heart failure in rats. Hypertension 45:1145-1152. doi:10.1161/ 01.HYP.0000168944.29525.da (Pubitemid 40770319)
11. Filusch A, Zelniker T, Baumgartner C, Eschricht S, Frey N, Katus HA, Chorianopoulos E (2011) Soluble TWEAK predicts hemodynamic impairment and functional capacity in patients with pulmonary arterial hypertension. Clin Res Cardiol 100:879-885. doi:10.1007/s00392-011-0318-z
12. Fukumoto Y, Shimokawa H (2011) Recent progress in the management of pulmonary hypertension. Circ J 75:1801-1810. doi:10.1253/circj.CJ-11-0567
13. Galie N, Manes A, Branzi A (2004) The endothelin system in pulmonary arterial hypertension. Cardiovasc Res 61:227-237. doi:10.1016/j.cardiores.2003. 11.026 (Pubitemid 38091763)
14. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, Kimura S, Masaki T, Duguid WP, Stewart DJ (1993) Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 328:1732-1739. doi: 10.1056/NEJM199306173282402 (Pubitemid 23170122)
15. Grimm PC, Nickerson P, Gough J, McKenna R, Stern E, Jeffery J, Rush DN (2003) Computerized image analysis of Sirius Red-stained renal allograft biopsies as a surrogate marker to predict long-term allograft function. JAmSoc Nephrol 14:1662-1668. doi: 10.1097/01.ASN.0000066143.02832.5E (Pubitemid 36687070)
16. Hamid SA, Bower HS, Baxter GF (2007) Rho kinase activation plays a major role as a mediator of irreversible injury in reperfused myocardium. Am J Physiol Heart Circ Physiol 292:H2598- H2606. doi:10.1152/ajpheart.01393.2006 (Pubitemid 47084509)
17. Hattori T, Shimokawa H, Higashi M, Hiroki J, Mukai Y, Tsutsui H, Kaibuchi K, Takeshita A (2004) Long-term inhibition of Rhokinase suppresses left ventricular remodeling after myocardial infarction in mice. Circulation 109:2234-2239. doi:10.1161/01. CIR.0000127939.16111.58 (Pubitemid 38625402)
18. Hoeper MM, Markevych I, Spiekerkoetter E, Welte T, Niedermeyer J (2005) Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 26:858-863. doi: 10.1183/09031936.05.00075305 (Pubitemid 41632043)
19. Hotta K, Sho M, Yamato I, Shimada K, Harada H, Akahori T, Nakamura S, Konishi N, Yagita H, Nonomura K, Nakajima Y (2011) Direct targeting of fibroblast growth factor-inducible 14 protein protects against renal ischemia reperfusion injury. Kidney Int 79:179-188. doi:10.1038/ki.2010.379
20. Jain M, Jakubowski A, Cui L, Shi J, Su L, Bauer M, Guan J, Lim CC, Naito Y, Thompson JS, Sam F, Ambrose C, Parr M, Crowell T, Lincecum JM, Wang MZ, Hsu YM, Zheng TS, Michaelson JS, Liao R, Burkly LC (2009) A novel role for tumor necrosis factorlike weak inducer of apoptosis (TWEAK) in the development of cardiac dysfunction and failure. Circulation 119:2058-2068. doi: 10.1161/CIRCULATIONAHA.108.837286
21. Jakubowski A, Ambrose C, Parr M, Lincecum JM, Wang MZ, Zheng TS, Browning B, Michaelson JS, Baetscher M, Wang B, Bissell DM, Burkly LC (2005) TWEAK induces liver progenitor cell proliferation. J Clin Invest 115:2330-2340. doi:10.1172/ JCI23486 (Pubitemid 41266195)
22. Kajstura J, Rota M, Cappetta D, Ogorek B, Arranto C, Bai Y, Ferreira-Martins J, Signore S, Sanada F, Matsuda A, Kostyla J, Caballero MV, Fiorini C, D'Alessandro DA, Michler RE, Del Monte F, Hosoda T, Perrella MA, Leri A, Buchholz BA, Loscalzo J, Anversa P (2012) Cardiomyogenesis in the aging and failing human heart. Circulation 126:1869-1881. doi:10.1161/ CIRCULATIONAHA.112.118380
23. Kleinbongard P, Heusch G, Schulz R (2010) TNFalpha in atherosclerosis, myocardial ischemia/reperfusion and heart failure. Pharmacol Ther 127:295-314. doi:10.1016/j.pharmthera.2010. 05.002
24. Krenning G, Zeisberg EM, Kalluri R (2010) The origin of fibroblasts and mechanism of cardiac fibrosis. J Cell Physiol 225:631-637. doi:10.1002/jcp.22322
25. Kuwahara K, Teg Pipes GC, McAnally J, Richardson JA, Hill JA, Bassel-Duby R, Olson EN (2007) Modulation of adverse cardiac remodeling by STARS, a mediator of MEF2 signaling and SRF activity. J Clin Invest 117:1324-1334. doi:10.1172/JCI31240 (Pubitemid 46718420)
26. Lamberts RR, Caldenhoven E, Lansink M, Witte G, Vaessen RJ, St Cyr JA, Stienen GJ (2007) Preservation of diastolic function in monocrotaline-induced right ventricular hypertrophy in rats. Am J Physiol Heart Circ Physiol 293:H1869-H1876. doi:10.1152/ ajpheart.00294.2007 (Pubitemid 47367237)
27. Lecour S, James RW (2011) When are pro-inflammatory cytokines SAFE in heart failure? Eur Heart J 32:680-685. doi:10.1093/ eurheartj/ehq484
28. Lynch CN, Wang YC, Lund JK, Chen YW, Leal JA, Wiley SR (1999) TWEAK induces angiogenesis and proliferation of endothelial cells. J Biol Chem 274:8455-8459. doi:10.1074/jbc. 274.13.8455 (Pubitemid 29164634)
29. Mayyas F, Niebauer M, Zurick A, Barnard J, Gillinov AM, Chung MK, Van Wagoner DR (2010) Association of left atrial endothelin-1 with atrial rhythm, size, and fibrosis in patients with structural heart disease. Circ Arrhythm Electrophysiol 3:369-379. doi:10.1161/CIRCEP.109.924985
30. Medjkane S, Perez-Sanchez C, Gaggioli C, Sahai E, Treisman R (2009) Myocardin-related transcription factors and SRF are required for cytoskeletal dynamics and experimental metastasis. Nat Cell Biol 11:257-268. doi:10.1038/ncb1833
31. Michaelson JS, Wisniacki N, Burkly LC, Putterman C (2012) Role of TWEAK in lupus nephritis: a bench-to-bedside review. J Autoimmu 39:130-142. doi:10.1016/j.jaut.2012.05.003
32. Miralles F, Posern G, Zaromytidou AI, Treisman R (2003) Actin dynamics control SRF activity by regulation of its coactivator MAL. Cell 113:329-342. doi:10.1016/S0092-8674(03)00278-2 (Pubitemid 36556115)
33. Mustonen E, Sakkinen H, Tokola H, Isopoussu E, Aro J, Leskinen H, Ruskoaho H, Rysa J (2010) Tumour necrosis factor-like weak inducer of apoptosis(TWEAK) and its receptor Fn14 during cardiac remodelling in rats. Acta Physiol (Oxf) 199:11-22. doi:10.1111/ j.1748-1716.2010.02080.x
34. Nischt R, Pottgiesser J, Krieg T, Mayer U, Aumailley M, Timpl R (1991) Recombinant expression and properties of the human calcium-binding extracellular matrix protein BM-40. Eur J Biochem 200:529-536. doi:10.1111/j.1432-1033.1991. tb16214.x
35. Novoyatleva T, Diehl F, van Amerongen MJ, Patra C, Ferrazzi F, Bellazzi R, Engel FB (2010) TWEAK is a positive regulator of cardiomyocyte proliferation. Cardiovasc Res 85:681-690. doi: 10.1093/cvr/cvp360
36. Park SH, Saleh D, Giaid A, Michel RP (1997) Increased endothelin- 1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist. Am J Respir Crit Care Med 156:600-608 (Pubitemid 27352001)
37. Pepke-Zaba J, Morrell NW (2005) The endothelin system and its role in pulmonary arterial hypertension (PAH). Thorax 60:443-444. doi:10.1136/thx.2004. 031724 (Pubitemid 40814040)
38. Polak JF, Holman BL, Wynne J, Colucci WS (1983) Right ventricular ejection fraction: an indicator of increased mortality in patients with congestive heart failure associated with coronary artery disease. J Am Coll Cardiol 2:217-224. doi:10.1016/S0735- 1097(83)80156-9 (Pubitemid 13078785)
39. Ren XD, Schwartz MA (2000) Determination of GTP loading on Rho. Methods Enzymol 325:264-272. doi:10.1016/S0076-6879 (00)25448-7
40. Rikitake Y, Oyama N, Wang CY, Noma K, Satoh M, Kim HH, Liao JK (2005) Decreased perivascular fibrosis but not cardiac hypertrophy in ROCK1 ± haploinsufficient mice. Circulation 112:2959-2965. doi:10.1161/CIRCULATIONAHA. 105.584623 (Pubitemid 41612298)
41. Sandoval J, Bauerle O, Palomar A, Gomez A, Martinez-Guerra ML, Beltran M, Guerrero ML (1994) Survival in primary pulmonary hypertension. Validation of a prognostic equation. Circulation 89:1733-1744. doi:10.1161/01.CIR.89.4.1733
42. Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, Roth M, Sydykov A, Lai YJ, Weissmann N, Seeger W, Grimminger F (2005) Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 115:2811-2821. doi:10.1172/JCI24838 (Pubitemid 41434408)
43. Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Herve P, Rainisio M, Simonneau G (2002) Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 40:780-788. doi: 10.1016/S0735-1097(02)02012-0 (Pubitemid 34925627)
44. Small EM, Thatcher JE, Sutherland LB, Kinoshita H, Gerard RD, Richardson JA, Dimaio JM, Sadek H, Kuwahara K, Olson EN (2010) Myocardin-related transcription factor-a controls myofibroblast activation and fibrosis in response to myocardial infarction. Circ Res 107:294-304. doi:10.1161/CIRCRESAHA. 110.223172
45. Stelzner TJ, O'Brien RF, Yanagisawa M, Sakurai T, Sato K, Webb S, Zamora M, Mc Murtry IF, Fisher JH (1992) Increased lung endothelin-1 production in rats with idiopathic pulmonary hypertension. Am J Physiol 262:L614-L620
46. Stewart DJ, Levy RD, Cernacek P, Langleben D (1991) Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med 114:464-469
47. Voelkel NF, Quaife RA, Leinwand LA, Barst RJ, McGoon MD, Meldrum DR, Dupuis J, Long CS, Rubin LJ, Smart FW, Suzuki YJ, Gladwin M, Denholm EM, Gail DB (2006) Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. Circulation 114:1883-1891. doi:10.1161/ CIRCULATIONAHA.106.632208 (Pubitemid 44673364)
48. Volz HC, Laohachewin D, Seidel C, Lasitschka F, Keilbach K, Wienbrandt AR, Andrassy J, Bierhaus A, Kaya Z, Katus HA, Andrassy M (2012) S100A8/A9 aggravates post-ischemic heart failure through activation of RAGE-dependent NF-kappaB signaling. Basic Res Cardiol 107:250. doi:10.1007/s00395-012- 0250-z
49. Wang DZ, Li S, Hockemeyer D, Sutherland L, Wang Z, Schratt G, Richardson JA, Nordheim A, Olson EN (2002) Potentiation of serum response factor activity by a family of myocardin-related transcription factors. Proc Natl Acad Sci USA 99:14855-14860. doi:10.1073/pnas.222561499 (Pubitemid 35334573)
50. Winkles JA (2008) The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov 7:411-425. doi:10.1038/nrd2488 (Pubitemid 351619113)
51. Yepes M, Brown SA, Moore EG, Smith EP, Lawrence DA, Winkles JA (2005) A soluble Fn14-Fc decoy receptor reduces infarct volume in a murine model of cerebral ischemia. Am J Pathol 166:511-520. doi:10.1016/S0002-9440(10)62273-0 (Pubitemid 40189047)
52. Yilmaz MI, Carrero JJ, Ortiz A, Martin-Ventura JL, Sonmez A, Saglam M, Yaman H, Yenicesu M, Egido J, Blanco-Colio LM (2009) Soluble TWEAK plasma levels as a novel biomarker of endothelial function in patients with chronic kidney disease. Clin J Am Soc Nephrol 4:1716-1723. doi:10.2215/CJN.02760409
53. Zhang X, Winkles JA, Gongora MC, Polavarapu R, Michaelson JS, Hahm K, Burkly L, Friedman M, Li XJ, Yepes M (2007) TWEAK-Fn14 pathway inhibition protects the integrity of the neurovascular unit during cerebral ischemia. J Cereb Blood Flow Metab 27:534-544. doi:10.1038/sj.jcbfm.9600368
54. Zhao Z, Burkly LC, Campbell S, Schwartz N, Molano A, Choudhury A, Eisenberg RA, Michaelson JS, Putterman C (2007) TWEAK/Fn14 interactions are instrumental in the pathogenesis of nephritis in the chronic graft-versus-host model of systemic lupus erythematosus. J Immunol 179:7949-7958
55. Zhu Y, Li T, Song J, Liu C, Hu Y, Que L, Ha T, Kelley J, Chen Q, Li C, Li Y (2011) The TIR/BB-loop mimetic AS-1 prevents cardiac hypertrophy by inhibiting IL-1R-mediated MyD88- dependent signaling. Basic Res Cardiol 106:787-799. doi: 10.1007/s00395-011-0182-z